We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · September 14, 2020

Pembrolizumab, Pembrolizumab/Chemotherapy, or Chemotherapy Alone in Advanced Gastric Cancer

JAMA Oncology


Additional Info

JAMA Oncology
Efficacy and Safety of Pembrolizumab or Pembrolizumab Plus Chemotherapy vs Chemotherapy Alone for Patients With First-Line, Advanced Gastric Cancer: The KEYNOTE-062 Phase 3 Randomized Clinical Trial
JAMA Oncol 2020 Sep 03;[EPub Ahead of Print], K Shitara, E Van Cutsem, YJ Bang, C Fuchs, L Wyrwicz, KW Lee, I Kudaba, M Garrido, HC Chung, J Lee, HR Castro, W Mansoor, MI Braghiroli, N Karaseva, C Caglevic, L Villanueva, E Goekkurt, H Satake, P Enzinger, M Alsina, A Benson, J Chao, AH Ko, ZA Wainberg, U Kher, S Shah, SP Kang, J Tabernero

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading